Skip to main content
NASDAQ:CMMB

Chemomab Therapeutics Competitors

$17.41
+0.82 (+4.94 %)
(As of 05/14/2021 12:51 PM ET)
Add
Compare
Today's Range
$17.11
$18.16
50-Day Range
$17.16
$55.00
52-Week Range
$12.32
$168.80
Volume922 shs
Average Volume216,297 shs
Market Capitalization$40.69 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Chemomab Therapeutics (NASDAQ:CMMB) Vs. LBPH, IPA, GANX, EVAX, LGVN, and VRDN

Should you be buying CMMB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Chemomab Therapeutics, including Longboard Pharmaceuticals (LBPH), ImmunoPrecise Antibodies (IPA), Gain Therapeutics (GANX), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), and Viridian Therapeutics (VRDN).

Chemomab Therapeutics (NASDAQ:CMMB) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Chemomab Therapeutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemomab TherapeuticsN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Chemomab Therapeutics and Longboard Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Chemomab Therapeutics and Longboard Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemomab Therapeutics00103.00
Longboard Pharmaceuticals00503.00

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Longboard Pharmaceuticals has a consensus target price of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher probable upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Chemomab Therapeutics.

Summary

Longboard Pharmaceuticals beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemomab TherapeuticsN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Earnings and Valuation

This table compares Chemomab Therapeutics and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/AN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemomab Therapeutics00103.00
ImmunoPrecise Antibodies01002.00

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than ImmunoPrecise Antibodies.

Summary

Chemomab Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemomab TherapeuticsN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Chemomab Therapeutics and Gain Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Gain Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemomab Therapeutics00103.00
Gain Therapeutics00203.00

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Gain Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 206.44%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Chemomab Therapeutics.

Summary

Gain Therapeutics beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemomab TherapeuticsN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Earnings and Valuation

This table compares Chemomab Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemomab Therapeutics00103.00
Evaxion Biotech A/S00203.00

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Evaxion Biotech A/S has a consensus target price of $18.00, suggesting a potential upside of 239.62%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Chemomab Therapeutics.

Summary

Evaxion Biotech A/S beats Chemomab Therapeutics on 2 of the 2 factors compared between the two stocks.

Chemomab Therapeutics (NASDAQ:CMMB) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Chemomab Therapeutics and Longeveron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemomab TherapeuticsN/AN/AN/A
LongeveronN/AN/AN/A

Earnings and Valuation

This table compares Chemomab Therapeutics and Longeveron's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/AN/AN/AN/A
LongeveronN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Chemomab Therapeutics and Longeveron, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemomab Therapeutics00103.00
Longeveron0000N/A

Chemomab Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Longeveron.

Summary

Chemomab Therapeutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Viridian Therapeutics and Chemomab Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Chemomab TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Viridian Therapeutics and Chemomab Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Chemomab TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Viridian Therapeutics and Chemomab Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Chemomab Therapeutics00103.00

Viridian Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 94.06%. Chemomab Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 141.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Viridian Therapeutics.


Chemomab Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.93+5.4%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.79+8.1%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.20+3.4%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60+6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.65+0.1%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.43+6.7%$37.69 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.31+13.0%$31.70 millionN/A0.00Upcoming Earnings
News Coverage
MYMD
MyMD Pharmaceuticals
0.0$3.58+1.7%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71+1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85+2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18+3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.95+16.5%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.35+0.9%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.60+7.7%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.